Pfizer Inc Portfolio Analysis: Q2 2026 Investment Activity
This analysis details Pfizer's significant stock sale in ORIC Pharmaceuticals during the second quarter of 2026, highlighting overall portfolio stability and sector concentration.
For Pfizer Inc, as reported for the period ending June 30th, 2026 (Q2), the investment landscape saw notable activity primarily centered around exits from specific holdings.
The most significant change during this quarter was a substantial reduction in shares held of ORIC Pharmaceuticals Inc (ORIC). Pfizer sold 4,407,497 shares, representing an approximate 92.2% decrease from the previous period.
This sale resulted in ORIC's portfolio allocation dropping significantly to just 2.09%. It is important to note that no other holdings listed were indicated as having experienced changes during this specific quarter by Pfizer according to the disclosed data.
Despite the notable exit from ORIC, the rest of Pfizer's portfolio remained static compared to prior periods. The company maintained its focus on the Healthcare sector, which accounted for nearly 99.98% (147,274,936) of its total portfolio value as of June 30th.
The remaining allocation in Pfizer's portfolio, amounting to $30,012 or approximately 0.02%, was categorized under 'Unknown' sectors based on the available information from this filing date.
Overall, Pfizer Inc's Q2 2026 activity appears focused on managing its existing positions rather than initiating new large purchases. The sole significant change observed during this quarter was the substantial reduction in ORIC Pharmaceuticals stock.